Revlimid’s approved indications
Celgene’s (CELG) Revlimid is the first oral medicine indicated for use in multiple myeloma (or MM) patients. The drug currently accounts for over half of Celgene’s total revenue.
During the first half of 2016, the drug earned $3.3 billion, ~62% of Celgene’s net product sales. Out of Revlimid’s total net product sales, its revenue from the US stood at $2.1 billion.
Revlimid, or lenalidomide, was first approved in December 2005 by the FDA for treating anemia associated with myelodysplastic syndromes (or MDS). In 2006, it was approved as a combination with dexamethasone in multiple myeloma patients who have one prior therapy.
In June 2013, the drug was approved for mantle cell lymphoma patients in cases where the disease relapsed or progressed after two prior therapies, including bortezomib as one therapy. Bortezomib, or Velcade, was developed by Millennium Pharmaceuticals and Johnson & Johnson (JNJ).
Growth prospects for Revlimid
With the highly successful newly diagnosed multiple myeloma (or NDMM) space launch, Revlimid is expected to earn $6.8 billion in 2016.
In the MM space, Revlimid competes with Amgen’s (AMGN) Kyprolis and Novartis’s (NVS) Farydak. For details on the drug, please read Strong Growth in Demand Could Boost Revlimid’s Sales in 2016.
According to its fiscal 2015 worldwide sales figures, Revlimid is the fourth largest–selling oncology drug. It is expected to be the best-selling oncology drug by 2021. In the next article, we’ll provide an update on Revlimid’s various ongoing lymphoma studies, which could drive its revenue.
Investing in the PowerShares QQQ ETF (QQQ) can offer you exposure to Celgene. QQQ holds ~1.6% of its total portfolio in Celgene.